Marketing Efforts for Anti-psychotics Brings on Lawsuits

October 3rd, 2010 New York Times contains a long analysis of the problems in the marketing of antipsychotic drugs. These efforts have included ghost-writing medical journal articles, under-the-table financial inducements to medical speakers and generally pushing to expand the diagnostic criteria while burying side effects. These efforts have reaped huge profits for the companies but [...]